Candriam SCA’s Rein Therapeutics RNTX Stock Holding History

Candriam SCA’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,128	Closed	-$28K	–	920
2021 Q2	$28K	Buy	+1,128	New	+$28.1K	﹤0.01%	853
2018 Q3	–	Sell	-7,500	Closed	-$813K	–	848
2018 Q2	$813K	Hold	7,500	–	–	0.01%	646
2018 Q1	$1.22M	Hold	7,500	–	–	0.02%	556
2017 Q4	$1.58M	Hold	7,500	–	–	0.03%	501
2017 Q3	$2.01M	Hold	7,500	–	–	0.04%	457
2017 Q2	$1.67M	Buy	+7,500	New	+$1.65M	0.03%	495

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Candriam SCA's RNTX Position: Q3 2021 in Review

Candriam SCA sold out of Rein Therapeutics (RNTX) in Q3 2021, closing a stake of 1,128 shares — an estimated $28K sold.

Candriam SCA first reported a position in RNTX in Q2 2017 and held it in 6 quarters. The position peaked at $2.01M in Q3 2017. 43 funds tracked by Wall St. Rank hold RNTX as of Q3 2021.

Candriam SCA reported no remaining Rein Therapeutics position as of Q3 2021 after selling out during the quarter.
Candriam SCA sold 1,128 Rein Therapeutics shares in Q3 2021, an estimated $28K.
Candriam SCA first reported a position in Rein Therapeutics in Q2 2017 and held it in 6 quarters.
Candriam SCA's Rein Therapeutics position peaked at $2.01M in Q3 2017.
43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.